Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Getaround, Inc reported the fiscal year ended December 31, 2022 results: revenue $59 million to $60 million.
- Period
- the fiscal year ended December 31, 2022
- Revenue
- $59 million to $60 million
- Result
- preliminary results
Exact text from the filing
expects to report the following preliminary unaudited condensed combined financial information for the full fiscal year ended December 31, 2022: • Total revenues in the range of $59 million to $60 million • Service revenue in the range of $57 million to $58 million • Gross margin from Service revenue in the range of 85% to 86% • Cash and cash equivalents of
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Getaround, Inc received a nyse deficiency notice notice regarding market value (rules 802.01B).
- Exchange
- nyse
- Notice
- deficiency notice
- Deficiency
- market value
- Rules
- 802.01B
Exact text from the filing
March 27, 2023, the Company received written notice from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the continued listing standard set forth in Section 802.01B of the NYSE Listed Company Manual because the average global market capitalization of the Company over a consecutive 30 trading-day period was less than $50 million and, at the same time, its last reported stockholders’ equity was less than $50 million. As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on February 1, 2023, the Com
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Getaround, Inc received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).
- Exchange
- nyse
- Notice
- deficiency notice
- Deficiency
- minimum bid price
- Rules
- 802.01C
Exact text from the filing
January 30, 2023 that it was not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period. In connection with the January notice, the Company notified the NYSE that it intends to cure the stock price deficiency and to return to compliance with the NYSE continued listing standard with respect to the deficiency under Section 802.01C. The Company is currently within the six-month cure period following receipt of the January notice. In accordance with the NYSE Li
View on SEC.gov